Biomedicine

Adult B-ALL exhibits significant heterogeneity and poor prognosis compared with the pediatric population. While the complete remission (CR)…

Patel, H. N. et al. J. Pharm. Bioallied Sci. 17, S1101–S3 (2025). Article PubMed PubMed Central Google Scholar …

These authors contributed equally: Yiming Qin, Tao Yan, Matthew Yu Heng Wong. School of Clinical Medicine, Beijing Tsinghua…

EHRSHOT database and prediction task The EHR data used in our experiments are from the EHRSHOT benchmark for…

Oxalic acid might do more than just contribute to the formation of kidney stones — it may also be an…

Health system learning We define ‘health system learning’ as learning directly from uncurated data generated during routine clinical…

Adapting prime editing for mammalian histone mutagenesis Mouse canonical histone H3 is encoded by nine H3.1 and three…

Aburomia R, Khaner O, Sidow A (2003) Functional evolution in the ancestral lineage of vertebrates or when genomic…

Despite excellent cure rates in Hodgkin lymphoma (HL) [1], 10–15% of patients experience primary treatment failure or long-term…

Design We conducted a pragmatic, multicenter, parallel-group cluster-randomized controlled trial across a network of 16 primary care facilities…

ParticipantsParticipation in BabyScreen+ and gNBS A total of 1139 participants consented to BabyScreen+ research, regardless of whether they…

A new study from the University of Bergen shows an association between breastfeeding up to six months of…

Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study